Results 161 to 170 of about 17,802 (177)
Some of the next articles are maybe not open access.

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

Journal of Neurology, 2022
Mathilda Mandel   +2 more
exaly  

Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

Clinical Immunology, 2012
Alexey Nikolaevich Boyko   +2 more
exaly  

Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

Journal of the Neurological Sciences, 2013
Yasuyuki Kihara, Jerold Chun
exaly  

Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions

Current Neurology and Neuroscience Reports, 2011
Matthias Mehling   +2 more
exaly  

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal, 2012
Byoung Joon Kim, Ju Hong Min
exaly  

Clinical activity after fingolimod cessation: disease reactivation or rebound?

European Journal of Neurology, 2018
Elisabetta Signoriello   +2 more
exaly  

Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use

Multiple Sclerosis Journal, 2015
Celia Chen
exaly  

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

Multiple Sclerosis Journal, 2016
Lucia Moiola   +2 more
exaly  

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

CNS Drugs, 2015
Samuel F. Hunter   +2 more
exaly  

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

Multiple Sclerosis Journal, 2014
Jeffrey A Cohen   +2 more
exaly  
multiple sclerosis
neurology
diseases of the nervous system
medicine
previous   15  16  17  18  

Home - About - Disclaimer - Privacy